223 related articles for article (PubMed ID: 28699267)
1. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.
Guérard N; Oder D; Nordbeck P; Zwingelstein C; Morand O; Welford RWD; Dingemanse J; Wanner C
Clin Pharmacol Ther; 2018 Apr; 103(4):703-711. PubMed ID: 28699267
[TBL] [Abstract][Full Text] [Related]
2. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
Guérard N; Morand O; Dingemanse J
Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
[TBL] [Abstract][Full Text] [Related]
3. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
4. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment.
Guérard N; Zwingelstein C; Dingemanse J
J Clin Pharmacol; 2017 Nov; 57(11):1425-1431. PubMed ID: 28618006
[TBL] [Abstract][Full Text] [Related]
5. Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects.
Boof ML; Halabi A; Ufer M; Dingemanse J
Eur J Clin Pharmacol; 2020 Mar; 76(3):431-437. PubMed ID: 31836927
[TBL] [Abstract][Full Text] [Related]
6. The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects.
Mueller MS; Sidharta PN; Voors-Pette C; Darpo B; Xue H; Dingemanse J
Orphanet J Rare Dis; 2020 Oct; 15(1):303. PubMed ID: 33109218
[TBL] [Abstract][Full Text] [Related]
7. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
[TBL] [Abstract][Full Text] [Related]
8. Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study.
Wanner C; Kimonis V; Politei J; Warnock DG; Üçeyler N; Frey A; Cornelisse P; Hughes D
Mol Genet Metab Rep; 2022 Jun; 31():100862. PubMed ID: 35782623
[TBL] [Abstract][Full Text] [Related]
9. Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase.
Abe A; Arend LJ; Lee L; Lingwood C; Brady RO; Shayman JA
Kidney Int; 2000 Feb; 57(2):446-54. PubMed ID: 10652021
[TBL] [Abstract][Full Text] [Related]
10. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
[TBL] [Abstract][Full Text] [Related]
11. Developments in the treatment of Fabry disease.
van der Veen SJ; Hollak CEM; van Kuilenburg ABP; Langeveld M
J Inherit Metab Dis; 2020 Sep; 43(5):908-921. PubMed ID: 32083331
[TBL] [Abstract][Full Text] [Related]
12. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
13. Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year.
Müntze J; Gensler D; Maniuc O; Liu D; Cairns T; Oder D; Hu K; Lorenz K; Frantz S; Wanner C; Nordbeck P
Clin Pharmacol Ther; 2019 May; 105(5):1224-1233. PubMed ID: 30506669
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
Feldt-Rasmussen U; Hughes D; Sunder-Plassmann G; Shankar S; Nedd K; Olivotto I; Ortiz D; Ohashi T; Hamazaki T; Skuban N; Yu J; Barth JA; Nicholls K
Mol Genet Metab; 2020; 131(1-2):219-228. PubMed ID: 33012654
[TBL] [Abstract][Full Text] [Related]
15. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data.
Riccio E; Zanfardino M; Ferreri L; Santoro C; Cocozza S; Capuano I; Imbriaco M; Feriozzi S; Pisani A;
Eur J Hum Genet; 2020 Dec; 28(12):1662-1668. PubMed ID: 32647377
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non-brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease.
Babcock M; Zheng J; Gail Shurr J; Li L; Wang B; Huertas P; Ryan PJ; Shen Y; Garovoy M
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):696-709. PubMed ID: 38363061
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
Giugliani R; Waldek S; Germain DP; Nicholls K; Bichet DG; Simosky JK; Bragat AC; Castelli JP; Benjamin ER; Boudes PF
Mol Genet Metab; 2013 May; 109(1):86-92. PubMed ID: 23474038
[TBL] [Abstract][Full Text] [Related]
18. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
[TBL] [Abstract][Full Text] [Related]
19. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.
Narita I; Ohashi T; Sakai N; Hamazaki T; Skuban N; Castelli JP; Lagast H; Barth JA
Clin Exp Nephrol; 2020 Feb; 24(2):157-166. PubMed ID: 31889231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
